Purpose: To evaluate the refractive development of premature infants with retinopathy of prematurity (ROP) after treatment with laser photocoagulation or intravitreal injection of bevacizumab (IVB). Methods: The medical records of patients with ROP treated between 2003 and 2012 who underwent yearly follow-ups were retrospectively reviewed. Patients with residual ROP abnormalities were excluded. The cycloplegic refraction at 3 years of age, assessed using an autorefractometer, was recorded. Results: In total, 54 eyes from 54 patients were enrolled. Patients were divided into 4 groups: group 1, including 14 eyes of 14 patients treated with laser therapy; group 2, 15 eyes of 15 patients treated with IVB; group 3, 13 eyes of 13 patients with non-type 1 ROP under conservative follow-up, and group 4, 12 eyes of 12 premature patients without ROP. The mean spherical equivalent at 3 years of age was -1.71 ± 1.27 dpt in group 1, -1.53 ± 2.20 dpt in group 2, 0.63 ± 1.37 dpt in group 3, and 0.41 ± 1.95 dpt in group 4. The mean refractive error differed significantly among the 4 groups (p < 0.001). Patients in groups 1 and 2 were more prone to myopia compared with those in groups 3 and 4. Furthermore, patients with type 1 ROP treated by laser photocoagulation (group 1) and those treated by IVB (group 2) had similar refraction (p = 1). Conclusions: The results of this study suggest that treatment-demanding ROP eyes are susceptible to more severe myopia with age compared with eyes without ROP or those with spontaneously regressed ROP. In addition, the myopic status between laser and IVB treatment did not differ statistically.

Keywords:
Retinopathy of prematurity, Laser, Vascular endothelial growth factor, Myopia, Refraction
1.
Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C: Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global level of 2010. Pediatr Res 2013;74(suppl 1):35-49.
2.
Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A; on behalf of the International NO-ROP Group: Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005;115: e518-e525.
3.
Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Tung B, Redford M; on behalf of the Early Treatment for Retinopathy of Prematurity Cooperative Group: Final visual results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2010;128:663-671.
4.
Kuo HK, Chen CC, Chen YH, Huang HC, Liu CA, Chen FS, Chung MY: Incidence and result of treatment-demanding retinopathy of prematurity using revised U.S. screening guidelines. Am J Perinatol 2012;29:827-831.
5.
Yang MB, Donovan EF: Risk analysis and an alternative protocol for reduction of screening for retinopathy of prematurity. J AAPOS 2009;13:539-545.
6.
Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001;119:1110-1118.
7.
Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1694.
8.
Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK: Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011;118:176-183.
9.
Mintz-Hittner HA, Kennedy KA, Chuang AZ; for the BEAT-ROP Cooperative Group: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-615.
10.
Chen J, Stahl A, Hellstrom A, Smith LE: Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr 2011;23:173-178.
11.
Salman AG, Said AM: Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res 2015;53:15-20.
12.
Gallo JE, Holmstrom G, Kugelberg U, Hedquist B, Lennerstrand G: Regressed retinopathy of prematurity and its sequelae in children aged 5-10 years. Br J Ophthalmol 1991;75:527-531.
13.
O'Connor AR, Stephenson TJ, Johnson A, Tobin MJ, Ratib S, Fielder AR: Change of refractive state and eye size in children of birth weight less than 1701 g. Br J Ophthalmol 2006;90:456-460.
14.
Chen TC, Tsai TH, Shih YF, Yeh PT, Yang CH, Hu FC, Lin LL, Yang CM: Long-term evaluation of refractive status and optical components in eyes of children born prematurely. Invest Ophthalmol Vis Sci 2010;51:6140-6148.
15.
Knight-Nanan DM, O'Keefe M: Refractive outcome in eyes with retinopathy of prematurity treated with cryotherapy or diode laser: 3 year follow up. Br J Ophthalmol 1996;80:998-1001.
16.
Connolly BP, Ng EYJ, McNamara JA, Regillo CD, Vander JF, Tasman W: A comparison of laser photocoagulation with cryotherapy for threshold retinopathy retinopathy of prematurity at 10 years: part 1. Refractive outcome. Ophthalmology 2002;109:936-941.
17.
Al-Ghamdi A, Albiani DA, Hodge WG, Clarke WN: Myopia and astigmatism in retinopathy of prematurity after treatment with cryotherapy or laser photocoagulation. Can J Ophthalmol 2004;39:521-525.
18.
Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB: Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013;155:1119-1124.
19.
Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA; for the BEAT-ROP Cooperative Group: Refractive outcome following bevacizumab monotherapy compared with conventional laser treatment. JAMA Ophthalmol 2014;132:1327-1333.
20.
Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus: Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572-576.
21.
An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 1984;102:1130-1134.
22.
Hsieh CJ, Liu JW, Huang JS, Lin KC: Refractive outcome of premature infants with or without retinopathy of prematurity a 2 years of age: a prospective controlled cohort study. Kaohsiung J Med Sci 2012;28:204-211.
23.
Wang J, Ren X, Shen L, Yanni SE, Leffler JN, Birch EE: Development of refractive error in individual children with regressed retinopathy of prematurity. Invest Ophthalmol Vis Sci 2013;54:6018-6024.
24.
Baker PS, Tasman W: Myopia in adults with retinopathy of prematurity. Am J Ophthalmol 2008;145:1090-1094.
25.
Yang CS, Wang AG, Shih YF, Hsu WM: Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol 2013;91:e276-e282.
26.
McLoone EM, O'Keefe M, McLoone SF, Lanigan BM: Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity. J AAPOS 2006;10:454-459.
27.
Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR: Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 2015;122:1008-1015.
28.
Kent D, Pennie F, Laws D, White S, Clark D: The influence of retinopathy of prematurity on ocular growth. Eye 2000;14:23-29.
29.
Sahni J, Subhedar NV, Clark D: Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomic outcomes at 6 months and 36 months. Br J Ophthalmol 2005;89:154-159.
30.
Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, Chan RV, Quiroz-Mercado H: Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 2013;33:329-338.
31.
Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, Hwang YS, Wang NK, Chen YP, Lee KH, Chuang CC, Chen TL, Lai CC, Wu WC: Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye 2014;28:1080-1087.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.